STOCK TITAN
  1. Home
  2. Sec-filings
  3. PACB
  4. [8-K] PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Reports Material Event

[8-K] PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Pacific Biosciences of California, Inc. reported that board member Christopher M. Smith resigned from the company’s board of directors, effective immediately on July 8, 2026. The company stated it is not aware of any disagreement with Mr. Smith regarding its operations, policies, or practices that led to his resignation.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Resignation effective date July 8, 2026 Christopher M. Smith’s board resignation effective immediately
Report signing date July 9, 2026 Date the 8-K was signed by General Counsel
Company phone (650) 521-8000 Registrant’s telephone number listed in the filing
board of directors financial
"Christopher M. Smith, a member of the board of directors (the “Board”) of Pacific Biosciences"
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
Emerging growth company regulatory
"Emerging growth company o o ITEM 5.02."
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Section 12(b) of the Act regulatory
"Securities registered pursuant to Section 12(b) of the Act"
Item 5.02 regulatory
"ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
0001299130false00012991302026-07-082026-07-08

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
July 8, 2026
Pacific Biosciences of California, Inc.
(Exact name of registrant as specified in its charter)
Delaware001-3489916-1590339
(State or other jurisdiction
of incorporation)		(Commission
File Number)		(IRS Employer
Identification No.)
1305 O’Brien Drive
Menlo Park, California 94025
(Address of principal executive offices) (Zip Code)
(650) 521-8000
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per sharePACBThe NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o


ITEM 5.02.    DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.
On July 8, 2026, Christopher M. Smith, a member of the board of directors (the “Board”) of Pacific Biosciences of California, Inc. (the “Company”), notified the Company of his resignation from the Board, effective immediately. The Company is not aware of any disagreement between Mr. Smith and the Company on any matter relating to the Company’s operations, policies or practices that resulted in Mr. Smith’s resignation.



SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Pacific Biosciences of California, Inc.
By:/s/ Brett Atkins
Brett Atkins
General Counsel
Date: July 9, 2026

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents

Other Documents